AMPE - Ampio Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
1.09
-0.02 (-1.80%)
At close: 4:00PM EDT

1.10 +0.01 (0.92%)
After hours: 4:09PM EDT

Stock chart is not supported by your current browser
Previous Close1.11
Open1.10
Bid1.05 x 5000
Ask1.12 x 100
Day's Range1.02 - 1.17
52 Week Range0.38 - 1.34
Volume889,769
Avg. Volume514,824
Market Cap74.37M
Beta0.50
PE Ratio (TTM)-5.27
EPS (TTM)-0.21
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • PR Newswire2 days ago

    Ampio Pharmaceuticals, Inc. Announces Closing of Registered Direct Offering

    ENGLEWOOD, Colo., Oct. 18, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) ("Ampio") today announced that it has closed it's previously announced registered direct offering of 7,709,400 shares of common stock at a purchase price of $0.875 per share for gross proceeds of approximately $6.75 million. The sale of the common stock was offered by Ampio pursuant to a shelf registration statement on Form S-3 (Registration No. 333-217094), which was declared effective by the Securities and Exchange Commission (the "SEC") on April 20, 2017. A final prospectus supplement was filed with the SEC and forms a part of the effective registration statement.

  • PR Newswire4 days ago

    Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering

    ENGLEWOOD, Colo., Oct. 16, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has entered into a securities purchase agreement with investors providing for the registered sale of approximately $6.75 million of shares of common stock at a purchase price of $0.875 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, including funding of the Ampion™ clinical trial. Joseph Gunnar & Co., LLC, and Fordham Financial Management, Inc. are acting as placement agents for the offering.

  • ACCESSWIRE7 days ago

    Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Ardelyx Inc.

    NEW YORK, NY / ACCESSWIRE / October 13, 2017 / Shares of both Ampio Pharmaceuticals (NYSE American: AMPE ) and Ardelyx Inc. (NASDAQ: ARDX ) soared on Thursday after both companies had data news, respectively. ...

  • PR Newswire8 days ago

    Ampio Announces Accepted Publication of Pooled Ampion™ Clinical Trial Results in Patients with Severe Osteoarthritis of the Knee

    ENGLEWOOD, Colo., Oct. 12, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that a manuscript titled: "LMWF-5A For The Treatment Of Severe Osteoarthritis Of The Knee: Integrated Analysis Of Safety And Efficacy" was accepted for publication in Orthopedics, an international peer-reviewed journal in the field of Orthopedics. Ampion™ is the Low Molecular Weight Fraction of 5% human serum Albumin (LMWF-5A). Ampio's Chief Scientific Officer, Dr. David Bar-Or described the study as follows: "This was a combined analysis of all completed single-injection Ampion™ randomized placebo-controlled trials to date, focusing on the subset of patients with severe (Kellgren-Lawrence [KL] grade 4) osteoarthritis of the knee (OAK).

  • PR Newswirelast month

    Ampio Completes Enrollment of Patients in 12-Week Pivotal Trial

    ENGLEWOOD, Colo., Sept. 18, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announces the completion of enrollment and dosing of patients in their pivotal single injection study on the "unmet medical need" of severe osteoarthritis of the knee (OAK).  These patients experience not only pain but also the loss of function and diminished quality of life. The primary endpoint of this pivotal trial follows the Osteoarthritis Research Society International (OARSI) guidance, utilizing the Outcome Measures in Rheumatology Clinical Trials (OMERACT) OMERACT-OARSI responder rate to address the signs and symptoms of severe OAK. Michael Macaluso, Ampio's CEO, noted, "Announcing the close of enrollment so quickly speaks to the unmet medical need.

  • PR Newswirelast month

    Ampio Pharmaceuticals, Inc. Announces Annual Shareholder Meeting

    ENGLEWOOD, Colo. , Sept. 8, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE: AMPE) a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent ...

  • PR Newswirelast month

    Ampio Pharmaceuticals, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

    ENGLEWOOD, Colo. , Sept. 7, 2017 /PRNewswire/ --   Ampio Pharmaceuticals, Inc. (NYSE: AMPE) a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent ...

  • PR Newswirelast month

    Ampio Discloses Receipt of Notice from NYSE American and Has Until March 1, 2019, to Gain Compliance

    ENGLEWOOD, Colo., Sept. 7, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE: American: AMPE) ("Ampio" or the "Company") announces that on September 1, 2017, it was notified by the NYSE American (the "Exchange") that the Company was not in compliance with certain of the Exchange's continued listing standards as set forth in Part 10 of the NYSE American Company Guide (the "Company Guide"). To maintain its listing on the Exchange, the Exchange has requested that the Company submit a plan of compliance (the "Plan") by October 2, 2017, addressing how it intends to regain compliance by March 1, 2019.

  • PR Newswire2 months ago

    Ampio Announces the Allowance of a Composition and Methods Patent in the USA Using Ampion™ in Conjunction with Stem Cells

    ENGLEWOOD, Colo., Aug. 8, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) is pleased to announce today the allowance of an important composition and methods patent in the USA complimenting a series of patents on Ampion™ (127 issued and 80 pending). The patent is entitled: "COMPOSITIONS FOR THE MOBILIZATION, HOMING, EXPANSION, AND DIFFERENTIATION OF STEM CELLS AND METHODS OF USING THE SAME."  The patent includes 34 allowed claims. Autologous or allogenic stem cells are used in clinical practice, including for osteoarthritis of the knee.

  • PR Newswire3 months ago

    Ampio Hosting Conference Call, Wednesday, July 12, 4:30 pm EDT

    ENGLEWOOD, Colo. , July 6, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT:  AMPE) hosting a conference call Wednesday, July 12th at 4:30 pm EDT . Participants are invited to dial in using the ...

  • PR Newswire4 months ago

    Ampio Injects First Patient in Final Pivotal Clinical Trial for Ampion™ BLA

    ENGLEWOOD, Colo., June 22, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) initiates dosing in the AP-003-C, Phase 3, single injection Ampion™ study.  This study addresses the "unmet medical need" in Kellgren-Lawrence (KL) grade 4 osteoarthritis of the knee (OAK), evaluating the efficacy of Ampion™ for the treatment of pain, function, and Patient Global Assessment (PGA) in severe OAK. The study's primary endpoint follows the Outcome Measures in Rheumatology Clinical Trials (OMERACT) and Osteoarthritis Research Society International (OARSI) guidance, utilizing the OMERACT-OARSI responder rate. Osteoarthritis (OA) is a progressive disorder of the joints involving degradation of the intra-articular cartilage, joint lining, ligaments, and bone.

  • PR Newswire4 months ago

    Ampio Announces Appointment of Interim Chief Financial Officer

    Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options.

  • PR Newswire4 months ago

    Ampio Pharmaceuticals, Inc. Announces Closing of Registered Direct Offering

    ENGLEWOOD, Colo., June 7, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ("Ampio") today announced that it has closed its previously announced registered direct offering of 10,990,245 shares of common stock and warrants to purchase up to 10,990,245 shares of common stock. The shares and warrants were sold in units, each of which is comprised of one share and a warrant to purchase one share of common stock. The warrants are exercisable six months following the date of issuance and will expire on the fifth anniversary of the initial date that the warrants become exercisable.

  • PR Newswire5 months ago

    Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering

    ENGLEWOOD, Colo., June 2, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has entered into a securities purchase agreement with investors providing for the registered sale of approximately $6.3 million of shares of common stock and accompanying warrants to purchase shares of common stock with an exercise price of $0.76 per share, at a combined purchase price of $0.60 per share and accompanying warrant to purchase one share of common stock. The warrants are exercisable six months after issuance and have a term of five years from the date of issuance. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, including funding of the Ampion™ clinical trial.

  • PR Newswire6 months ago

    Ampion™ Human Macrophage Study Results Accepted for Presentation at the 2017 Annual AAST Meeting in Baltimore

    ENGLEWOOD, Colo., May 5, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today that the results of a scientific study entitled "The Effect of LMWF5A (Ampion™) on Differentiated ...

  • PR Newswire6 months ago

    Ampio Initiates Pivotal Trial of Ampion™

    ENGLEWOOD, Colo., May 1, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announces initiation of a single injection study to meet the "unmet medical need" of treating the severe pain and loss of function associated with Kellgren-Lawrence (KL) grade 4 osteoarthritis of the knee (OAK) with a primary endpoint that follows the Osteoarthritis Research Society International (OARSI) guidance, utilizing the Outcome Measures in Rheumatology Clincal Trials (OMERACT) OMERACT-OARSI responder rate.

  • PR Newswire7 months ago

    Ampio Pharmaceuticals Amends Warrant Agreement

    ENGLEWOOD, Colo., March 28, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), a leader in the development of Ampion™, a low molecular weight fraction of human serum albumin with anti-inflammatory properties, announced that it entered into a Waiver and Consent Letter Agreement with CVI Investments, Inc., amending the terms of warrants previously issued to CVI on September 1, 2016. Under the Waiver and Consent Agreement, CVI waived the right to have its warrant exercise price reduced, and the number of Ampio shares of Common Stock underlying the warrant increased in the event the Company secures any financing, including debt, which includes issuing or selling shares of Common Stock for a price per share less than the warrant exercise price. CVI also waived the prohibition on Ampio's ability to issue or sell shares of its Common Stock, options or convertible securities at a price which varies or may vary with the market price of the Common Stock or pursuant to an equity credit line or similar "at-the-market" type offering.

  • PR Newswire7 months ago

    Ampio Updates Intellectual Property and Regulatory Exclusivity Strategy to Support the Commercialization of Ampion™

    ENGLEWOOD, Colo., March 23, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announces the issuance of China Patent No 102210852 B for the production of an active ingredient of Ampion™, which completes the intellectual property protection in China. Mr. Macaluso, Ampio's CEO, noted that "With the issuance of this patent, the Company's two-prong strategy to obtain comprehensive and overlapping Intellectual Property and Regulatory Exclusivity protection for a commercial launch of Ampion™, expected in 2018, is nearing completion.

  • PR Newswire7 months ago

    Update - Ampio Pharmaceuticals Provides Corporate Update

    ENGLEWOOD, Colo., March 22, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), a leader in the development of Ampion™, a low molecular weight fraction of human serum albumin with anti-inflammatory properties, today announced that it is re-issuing its previous release that was made on March 20, 2017 to incorporate certain disclosures that are required under the NYSE MKT Company Guide Sections 401(h) and 610(b). Included below are these additional disclosures along with the previously disclosed update of corporate activities. As stated in a press release dated February 27, 2017, having recently concluded a successful series of meetings with the US Food and Drug Administration ("FDA"), Ampio is preparing to initiate what is anticipated to be the final pivotal trial of Ampion™ to treat the severe pain associated with Kellgren-Lawrence grade 4 osteoarthritis of the knee ("OAK").

  • PR Newswire7 months ago

    Ampio Pharmaceuticals Provides Corporate Update

    ENGLEWOOD, Colo., March 20, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), a leader in the development of Ampion™, a low molecular weight fraction of human serum albumin with anti-inflammatory properties, announced an update of corporate activities.  As stated in a press release dated February 27, 2017, having recently concluded a successful series of meetings with the US Food and Drug Administration ("FDA"), Ampio is preparing to initiate what is anticipated to be the final pivotal trial of Ampion™ to treat the severe pain associated with Kellgren-Lawrence grade 4 osteoarthritis of the knee ("OAK"). As recommended by the FDA, the proposed primary endpoint for this study follows OARSI guidance, utilizing the OMERACT-OARSI responder rate. In addition, Ampio plans to advance all necessary Biologic License Application (BLA) activities in parallel to expedite the path to potential FDA approval.

  • PR Newswire8 months ago

    Ampio Hosting Conference Call Tuesday, March 7, 4:30pm EST

    ENGLEWOOD, Colo., March 1, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT:  AMPE) will host an investor conference call Tuesday, March 7 th at 4:30 pm EST. Participants are invited to dial-in ...

  • PR Newswire8 months ago

    Ampio Receives Guidance from the FDA and Proposes a Path for Approval for Single-Injection Ampion™ for the Treatment of Pain Due to Severe Osteoarthritis of the Knee

    ENGLEWOOD, Colo., Feb. 27, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced that the Office of Tissue and Advanced Therapies (OTAT), a branch of the Center for Biologics Evaluation and Research (CBER) of the FDA, has recently provided additional guidance for the path to approval of Ampion™ as a treatment for pain due to severe Osteoarthritis of the knee (OAK). The FDA acknowledged an unmet medical need in patients with pain due to severe OAK, graded as Kellgren-Lawrence Grade 4 (KL 4), where there are currently no FDA approved treatments for this population.